摘要
棘皮动物微管结合蛋白4(EML4)-间变淋巴瘤激酶(ALK)融合基因作为近几年新发现的肿瘤相关基因,在多种肿瘤组织中表达。目前针对EML4-ALK融合基因的研究仍以非小细胞肺癌为主,以该融合基因为治疗靶点的ALK抑制剂已经逐渐推向临床。EML4-ALK融合基因与表皮生长因子受体(EGFR)-Kras突变相关性的研究亦为肿瘤的靶向治疗提供了新思路。
EML4-ALKfusiongeneisoneofthenoveltargetsinthetherapyoflungcancer,whichcan be detected in several kinds of tumors.A specific ALK inhibitor has been shown to exert anti-tumor effects in non-small cell lung cancer with the EML4-ALK fusion gene.Correlative study between EML4-ALK gene fusion and EGFR-Kras mutations might cast new insight on the tumor target therapy.
出处
《国际肿瘤学杂志》
CAS
2014年第7期484-487,共4页
Journal of International Oncology
作者简介
通信作者:岳文涛,E-mail:yuewt2000@yahoo.com